The Natural Product Essramycin and Three of Its Isomers Are Devoid of Antibacterial Activity
作者:Huan Wang、Dusan Hesek、Mijoon Lee、Elena Lastochkin、Allen G. Oliver、Mayland Chang、Shahriar Mobashery
DOI:10.1021/acs.jnatprod.6b00057
日期:2016.4.22
essramycin, a natural productfrom a marine Streptomyces species isolated from the Egyptian Mediterranean coast, were synthesized. The structures for the isomers were assigned unequivocally by 1H NMR, 13C NMR, high-resolution mass spectrometry, and X-raycrystalstructure determinations. Notwithstanding the earlier report of broad-spectrum antibacterial activity for the natural product, none of the four
合成了埃斯霉素的四种可能的异构体,该埃斯霉素是从埃及地中海沿岸分离的海洋链霉菌属物种的天然产物。通过1 H NMR,13 C NMR,高分辨率质谱和X射线晶体结构确定明确地分配了异构体的结构。尽管较早报道了天然产物的广谱抗菌活性,但四种异构体均未显示出任何此类活性。
A Short Synthesis of the Triazolopyrimidine Antibiotic Essramycin
作者:Ugo Battaglia、Christopher J. Moody
DOI:10.1021/np100298m
日期:2010.11.29
A shortsynthesis of the 1,2,4-triazolo[1,5-a]pyrimidine antibiotic essramycin is described involving condensation of aminoguanidine with ethyl benzoylacetate to give an amino-1,2,4-triazole, followed by condensation with ethyl acetoacetate to form the pyrimidone ring.
描述了1,2,4-三唑并[1,5- a ]嘧啶类抗生素埃斯霉素的简短合成,包括将氨基胍与苯甲酰乙酸乙酯缩合,得到氨基1,2,4-三唑,然后与乙酰乙酸乙酯缩合形成嘧啶酮环。
Synthesis of Essramycin and Comparison of Its Antibacterial Activity
作者:Ernest H. L. Tee、Tomislav Karoli、Soumya Ramu、Johnny X. Huang、Mark S. Butler、Matthew A. Cooper
DOI:10.1021/np100648q
日期:2010.11.29
The triazolopyrimidine natural product essramycin (1) was synthesized without the use of protecting groups via a two-step reaction scheme involving a 3-amino-1,2,4-triazole intermediate, and its structure was unequivocally determined. However, in contrast to the natural product, the synthetic essramycin (1) did not display any antibacterial activity.
NOVEL METHODS, COMPOUNDS, AND COMPOSITIONS FOR INHIBITION OF ROS
申请人:GRUENEBERG Dorre A.
公开号:US20160031890A1
公开(公告)日:2016-02-04
The present invention relates to a method using some novel compounds and compositions for the inhibition of ROS tyrosine kinase. In particular, the present invention covers a method to treat abnormal cell growth, such as cancer, with ROS
10
inhibitors and compositions having ROS inhibitors. An illustrative compound of the invention is shown below Formula (I).